ARIX.L - Arix Bioscience plc

LSE - LSE Delayed Price. Currency in GBp
111.50
0.00 (0.00%)
At close: 5:09PM BST
Stock chart is not supported by your current browser
Previous Close111.50
Open110.60
Bid0.00 x 0
Ask0.00 x 0
Day's Range110.10 - 113.00
52 Week Range110.10 - 182.00
Volume46,250
Avg. Volume28,235
Market Cap151.14M
Beta (3Y Monthly)-0.05
PE Ratio (TTM)3.89
EPS (TTM)28.70
Earnings DateApr 27, 2018 - Apr 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est295.33
  • PR Newswire

    Arix Bioscience plc: Imara Presents initial Phase 2a data for IMR-687

    Arix Bioscience plc (ARIX.L) ("Arix"), a global venture capital company focused on investing and building breakthrough biotech companies, notes that its portfolio company Imara, Inc. ("Imara") has presented positive initial data from its ongoing Phase 2a clinical trial evaluating the safety and efficacy of IMR-687, its lead programme for the treatment of Sickle Cell Disease, at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The announcement can be accessed on Imara's website http://imaratx.com/who-we-are/news-press-releases/ and the full text of the announcement from Imara is contained below.

  • PR Newswire

    Arix Bioscience plc: Aura Completes $40 Million Series D Financing

    Arix Bioscience plc ("Arix") (ARIX.L) a global venture capital company focused on investing and building breakthrough biotech companies, today announces that it has committed $4.5 million (£3.4 million[1]) to the $40 million (£31 million) Series D financing ("the financing") of Aura Biosciences ("Aura"), a leader in the development of novel targeted therapies in ocular oncology. Following this commitment, Arix increases its stake to 7.7% on a fully diluted basis.

  • PR Newswire

    Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR

    Arix Bioscience plc (ARIX.L) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Autolus Therapeutics plc (AUTL) ("Autolus"), has announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The announcement can be accessed on Autolus' investor website at https://www.autolus.com/investor-relations and full text of the announcement from Autolus is contained below.

  • PR Newswire

    Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019

    LONDON , March 29, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes ...

  • PR Newswire

    Arix Bioscience plc: Arix Co-leads $63 Million Series B Investment Round for Imara

    Arix Bioscience plc ("Arix") (ARIX.L), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. ("Imara"), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease ("SCD") and other hemoglobinopathies. As part of the financing, Arix has committed to invest $15.0 million (£11.3 million) for a 10% stake on a fully diluted basis.

  • PR Newswire

    Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial

    LONDON , February 19, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, notes that its portfolio company, ...

  • PR Newswire

    Arix Bioscience plc: Management and Board Changes

    Arix Bioscience plc (ARIX.L) ("Arix" or the "Company"), a global healthcare and life science company supporting medical innovation, today announces that Chief Investment Officer, Joe Anderson, has been reappointed as Chief Executive Officer and will re-join the Arix Board. Jonathan Peacock, Executive Chairman, will become Non-Executive Chairman and Sir Christopher Evans will retire from the Board, remaining a consultant to the Company.

  • PR Newswire

    Arix Bioscience plc: Harpoon Closes Initial Public Offering

    Arix Bioscience plc (ARIX.L) ("Arix"), a global healthcare and life science company supporting medical innovation notes one of its portfolio companies, Harpoon Therapeutics, Inc. (HARP) ("Harpoon") a clinical-stage immunotherapy company developing a novel class of T cell engagers, has reported the closing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share for gross proceeds of $75.6 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon.

  • PR Newswire

    Arix Bioscience plc: Harpoon Announces Proposed Public Offering in the United States

    Arix Bioscience plc (ARIX.L) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its portfolio company Harpoon Therapeutics, Inc. ("Harpoon") has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed underwritten initial public offering in the United States of shares of Harpoon's common stock. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective.

  • PR Newswire

    Arix Bioscience plc: Arix Appoints Dr Christian Schetter as Entrepreneur in Residence (EIR)

    Arix Bioscience plc (ARIX.L) ("Arix"), a global healthcare and life science company supporting medical innovation, today announces the appointment of Dr Christian Schetter as Entrepreneur in Residence (EIR). Christian has over 20 years' industry experience across the life sciences sector, and joins Arix from German immuno-oncology company Rigontec GmbH, where he was CEO for four years before its acquisition by MSD.

  • PR Newswire

    Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes

    LONDON , December 3, 2018 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes its portfolio company, Autolus ...

  • PR Newswire

    Arix Bioscience plc: Autolus Presents Initial AUTO3 Clinical Data at ASH

    LONDON , December 3, 2018 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its portfolio company, ...

  • PR Newswire

    Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound

    Arix Bioscience plc ("Arix") (ARIX.L), a global healthcare and life science company supporting medical innovation, is pleased to note that Pharmaxis Ltd (PXS.AX), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF). Arix led the A$24 million (£13.4 million) financing for Pharmaxis in August, acquiring an 11.1% equity stake.

  • PR Newswire

    Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round

    LONDON , November 12, 2018 /PRNewswire/ -- This Announcement Contains Inside Information Within the Meaning of the EU Market Abuse Regulation No.596/2014 Arix ' s total interest in Harpoon increases to ...

  • PR Newswire

    Autolus Therapeutics to Present New Data at the ASH Annual Meeting

    LONDON , November 2, 2018 /PRNewswire/ -- Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes one of its Group Businesses, ...

  • PR Newswire

    Arix Bioscience plc - Aura Biosciences Reports Positive Phase 1b/2 Clinical Data for AU-011

    Arix Bioscience plc ("Arix") (ARIX.L), a global healthcare and life science company supporting medical innovation, is pleased to note that Aura Biosciences ("Aura"), a leader in the development of novel targeted therapies in ocular oncology, has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, its lead product candidate for the primary treatment of choroidal melanoma. Joe Anderson, CIO of Arix, commented: "Ocular melanoma is the most common primary cancer of the eye.

  • PR Newswire

    Arix Bioscience plc - Arix to Host Oncology KOL Event on October 30, 2018

    LONDON , October 25, 2018 /PRNewswire/ -- Webcast to begin at 12:00pm ET Focus on recent developments in synthetic lethality and bi-specific antibodies within oncology Arix Bioscience plc (LSE: ARIX) ("Arix"), ...

  • PR Newswire

    Arix Bioscience plc - LogicBio Announces Closing of Initial Public Offering

    LONDON , October 24, 2018 /PRNewswire/ -- This Announcement Contains Inside Information Within the Meaning of the EU Market Abuse Regulation No.596/2014 LogicBio IPO has closed Arix retains a stake of ...

  • PR Newswire

    Arix Bioscience plc: LogicBio Prices Nasdaq IPO

    LONDON , October 19, 2018 /PRNewswire/ -- THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014  Third public listing of an Arix company, three ...

  • PR Newswire

    Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound

    Arix Bioscience plc ("Arix") (ARIX.L), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Pharmaxis Ltd (PXS.AX), an Australian pharmaceutical research company focused on inflammation and fibrosis, today announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF). The announcement can be accessed on Pharmaxis' website at http://www.pharmaxis.com.au/investor-centre/news/ and full text of the announcement from Pharmaxis is contained below.

  • PR Newswire

    Arix Bioscience plc: Update on LogicBio Proposed Initial Public Offering in the United States

    Arix Bioscience plc (ARIX.L) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that LogicBio Therapeutics Inc.("LogicBio") has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering in the United States of shares of its common stock. The registration statement discloses an indicative pricing range for the proposed offering of U.S.$12.00- U.S.$14.00 per common share.

  • PR Newswire

    Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio

    LONDON , October 1, 2018 /PRNewswire/ -- This Announcement Contains Inside Information Within The Meaning Of The EU Market Abuse Regulation No.596/2014 Arix co-leads a $58 million Series A investment in ...